Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

2017; Springer Science+Business Media; Volume: 80; Issue: 6 Linguagem: Inglês

10.1007/s00280-017-3451-1

ISSN

1432-0843

Autores

Martin J. van den Bent, Hui Gan, Andrew B. Lassman, Priya Kumthekar, Ryan Merrell, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Burt Nabors, Kyriakos P. Papadopoulos, Marta Peñas-Prado, John Simes, Helen Wheeler, Tobias Walbert, Andrew M. Scott, Erica Gomez, Ho‐Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle Bain, Peter Ansell, Kyle D. Holen, David Maag, David A. Reardon,

Tópico(s)

Cancer, Hypoxia, and Metabolism

Resumo

Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody-drug conjugate that preferentially binds cells with EGFR amplification, is internalized and releases a potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, and efficacy of depatux-m monotherapy at the recommended Phase 2 dose (RPTD) in patients with EGFR-amplified, rGBM.

Referência(s)